Melatonin in Children with Autism Spectrum Disorders: Endogenous and Pharmacokinetic Profiles in Relation to Sleep

Suzanne E. Goldman, Karen W. Adkins, M. Wade Calcutt, Melissa D. Carter, Robert L. Goodpaste, Lily Wang, Yaping Shi, Helen J. Burgess, David L. Hachey, Beth A. Malow

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Supplemental melatonin has been used to treat sleep onset insomnia in children with autism spectrum disorders (ASD), although the mechanism of action is uncertain. We assessed endogenous and supplemental melatonin profiles in relation to sleep in nine children with ASD. In endogenous samples, maximal melatonin concentration (Cmax) and time to peak concentration (Tmax) were comparable to those previously published in the literature for typically developing children, and dim light melatonin onsets were captured in the majority of children. In treatment samples (supplemental melatonin), melatonin parameters were also comparable to those previously published for typically developing children. Our findings support that children with ASD and insomnia responsive to low dose melatonin treatment have relatively normal profiles of endogenous and supplemental melatonin.

Original languageEnglish (US)
Pages (from-to)2525-2535
Number of pages11
JournalJournal of Autism and Developmental Disorders
Volume44
Issue number10
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Melatonin
Sleep
Pharmacokinetics
Sleep Initiation and Maintenance Disorders
Autism Spectrum Disorder
Light
Therapeutics

Keywords

  • Dim light melatonin onset
  • Insomnia
  • N-acetylserotonin

ASJC Scopus subject areas

  • Developmental and Educational Psychology

Cite this

Melatonin in Children with Autism Spectrum Disorders : Endogenous and Pharmacokinetic Profiles in Relation to Sleep. / Goldman, Suzanne E.; Adkins, Karen W.; Calcutt, M. Wade; Carter, Melissa D.; Goodpaste, Robert L.; Wang, Lily; Shi, Yaping; Burgess, Helen J.; Hachey, David L.; Malow, Beth A.

In: Journal of Autism and Developmental Disorders, Vol. 44, No. 10, 01.01.2014, p. 2525-2535.

Research output: Contribution to journalArticle

Goldman, SE, Adkins, KW, Calcutt, MW, Carter, MD, Goodpaste, RL, Wang, L, Shi, Y, Burgess, HJ, Hachey, DL & Malow, BA 2014, 'Melatonin in Children with Autism Spectrum Disorders: Endogenous and Pharmacokinetic Profiles in Relation to Sleep', Journal of Autism and Developmental Disorders, vol. 44, no. 10, pp. 2525-2535. https://doi.org/10.1007/s10803-014-2123-9
Goldman, Suzanne E. ; Adkins, Karen W. ; Calcutt, M. Wade ; Carter, Melissa D. ; Goodpaste, Robert L. ; Wang, Lily ; Shi, Yaping ; Burgess, Helen J. ; Hachey, David L. ; Malow, Beth A. / Melatonin in Children with Autism Spectrum Disorders : Endogenous and Pharmacokinetic Profiles in Relation to Sleep. In: Journal of Autism and Developmental Disorders. 2014 ; Vol. 44, No. 10. pp. 2525-2535.
@article{bdd15f4110fc4c4380f639b231c8a1d1,
title = "Melatonin in Children with Autism Spectrum Disorders: Endogenous and Pharmacokinetic Profiles in Relation to Sleep",
abstract = "Supplemental melatonin has been used to treat sleep onset insomnia in children with autism spectrum disorders (ASD), although the mechanism of action is uncertain. We assessed endogenous and supplemental melatonin profiles in relation to sleep in nine children with ASD. In endogenous samples, maximal melatonin concentration (Cmax) and time to peak concentration (Tmax) were comparable to those previously published in the literature for typically developing children, and dim light melatonin onsets were captured in the majority of children. In treatment samples (supplemental melatonin), melatonin parameters were also comparable to those previously published for typically developing children. Our findings support that children with ASD and insomnia responsive to low dose melatonin treatment have relatively normal profiles of endogenous and supplemental melatonin.",
keywords = "Dim light melatonin onset, Insomnia, N-acetylserotonin",
author = "Goldman, {Suzanne E.} and Adkins, {Karen W.} and Calcutt, {M. Wade} and Carter, {Melissa D.} and Goodpaste, {Robert L.} and Lily Wang and Yaping Shi and Burgess, {Helen J.} and Hachey, {David L.} and Malow, {Beth A.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s10803-014-2123-9",
language = "English (US)",
volume = "44",
pages = "2525--2535",
journal = "Journal of Autism and Developmental Disorders",
issn = "0162-3257",
publisher = "Springer New York",
number = "10",

}

TY - JOUR

T1 - Melatonin in Children with Autism Spectrum Disorders

T2 - Endogenous and Pharmacokinetic Profiles in Relation to Sleep

AU - Goldman, Suzanne E.

AU - Adkins, Karen W.

AU - Calcutt, M. Wade

AU - Carter, Melissa D.

AU - Goodpaste, Robert L.

AU - Wang, Lily

AU - Shi, Yaping

AU - Burgess, Helen J.

AU - Hachey, David L.

AU - Malow, Beth A.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Supplemental melatonin has been used to treat sleep onset insomnia in children with autism spectrum disorders (ASD), although the mechanism of action is uncertain. We assessed endogenous and supplemental melatonin profiles in relation to sleep in nine children with ASD. In endogenous samples, maximal melatonin concentration (Cmax) and time to peak concentration (Tmax) were comparable to those previously published in the literature for typically developing children, and dim light melatonin onsets were captured in the majority of children. In treatment samples (supplemental melatonin), melatonin parameters were also comparable to those previously published for typically developing children. Our findings support that children with ASD and insomnia responsive to low dose melatonin treatment have relatively normal profiles of endogenous and supplemental melatonin.

AB - Supplemental melatonin has been used to treat sleep onset insomnia in children with autism spectrum disorders (ASD), although the mechanism of action is uncertain. We assessed endogenous and supplemental melatonin profiles in relation to sleep in nine children with ASD. In endogenous samples, maximal melatonin concentration (Cmax) and time to peak concentration (Tmax) were comparable to those previously published in the literature for typically developing children, and dim light melatonin onsets were captured in the majority of children. In treatment samples (supplemental melatonin), melatonin parameters were also comparable to those previously published for typically developing children. Our findings support that children with ASD and insomnia responsive to low dose melatonin treatment have relatively normal profiles of endogenous and supplemental melatonin.

KW - Dim light melatonin onset

KW - Insomnia

KW - N-acetylserotonin

UR - http://www.scopus.com/inward/record.url?scp=84912046248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912046248&partnerID=8YFLogxK

U2 - 10.1007/s10803-014-2123-9

DO - 10.1007/s10803-014-2123-9

M3 - Article

C2 - 24752680

AN - SCOPUS:84912046248

VL - 44

SP - 2525

EP - 2535

JO - Journal of Autism and Developmental Disorders

JF - Journal of Autism and Developmental Disorders

SN - 0162-3257

IS - 10

ER -